Revlimid and Renal impairment - a phase IV clinical study of FDA data

Summary:

Renal impairment is reported as a side effect among people who take Revlimid (lenalidomide), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Dexamethasone, and have High blood pressure.

The phase IV clinical study analyzes which people have Renal impairment when taking Revlimid. It is created by eHealthMe based on reports of 377,717 people who have side effects when taking Revlimid from the FDA, and is updated regularly.

What is Revlimid?

Revlimid has active ingredients of lenalidomide. It is often used in multiple myeloma. eHealthMe is studying from 378,026 Revlimid users. Check the latest studies of Revlimid.

What is Renal impairment?

Renal impairment (severely reduced kidney function) is found to be associated with 2,209 drugs and 2,471 conditions by eHealthMe. Check the latest studies of Renal impairment.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

377,717 people reported to have side effects when taking Revlimid.
Among them, 2,361 people (0.63%) have Renal impairment.

Among these 2,361 people:

* Approximation only. Some reports may have incomplete information.

Do you take Revlimid and have Renal impairment?

- Check whether Renal impairment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Revlimid:

Revlimid (378,026 reports)

Renal impairment treatments and more:

Renal impairment (99,633 reports)

How severe was Renal impairment and when was it recovered:

Renal impairment in Revlimid

Expand to all the drugs that have ingredients of lenalidomide:

Renal impairment and drugs with ingredients of lenalidomide

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Revlimid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Renal impairment:

Renal impairment (2,209 drugs)

Browse all the conditions that are associated with Renal impairment:

Renal impairment (2,471 conditions)

Related publications that referenced our studies

Al-Hamdy RA, "Assessment of electrolytes and HbA1c in type 2 diabetic patients using metformin and evaluation of guidelines obedience regarding renal impairment", J.Thi-Qar Sci., 2015 Jan .
Al-Hamdy RA, "Assessment of electrolytes and HbA1c in type 2 diabetic patients using metformin and evaluation of guidelines obedience regarding renal impairment", J.Thi-Qar Sci., 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lenalidomide (the active ingredients of Revlimid) and Revlimid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.